Tenaya Therapeutics, Inc.'s Chief Medical Officer (CMO), Tingley Whittemore, executed a transaction involving the disposition of common stock valued at $2,476 on May 18, 2026. The specific details of the sale involved the disposal of 3,121 shares at an average price of $0.79 per share.
This insider activity was reported during a period of notable volatility for the biotech firm. Over the preceding seven days, Tenaya's shares had fallen by 21%. The stock was trading near the sale price of $0.79, which positioned it within its 52-week range of $0.39 to $2.35.
Details of the Transaction and Holdings
The disposition of these shares was necessary to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) that were originally awarded on January 24, 2025. Following this specific transaction, Ms. Whittemore's direct holdings of Tenaya Therapeutics common stock totaled 215,497 shares. This total figure incorporates an additional allotment of 112,919 shares of common stock that are scheduled to be issued to her upon the future vesting of restricted stock units.
From a valuation perspective, independent analysis suggests Tenaya may currently be undervalued at its existing market levels. The platform tracking these insights notes ten additional ProTips available for investors who seek more comprehensive understanding regarding the company's current $172.5 million market capitalization.
Despite the reported insider sale, recent developments concerning Tenaya Therapeutics’ pipeline suggest a period of substantial clinical and scientific advancement for the organization.
The company recently released interim results from its RIDGE-1 Phase 1b/2 clinical trial. This study specifically evaluated the use of TN-401 gene therapy in patients diagnosed with arrhythmogenic right ventricular cardiomyopathy. The trial outcomes were characterized as promising, noting that all six participating patients experienced significant reductions in premature ventricular contractions after receiving the therapeutic treatment.
Further enhancing its scientific profile, Tenaya plans to present detailed clinical data derived from this RIDGE-1 trial at an upcoming industry event: the American Society of Gene and Cell Therapy Annual Meeting. The company's advancements are not limited to this single area; they also shared preclinical data demonstrating that its HDAC6 inhibitor, TN-301, improved muscle function in models used for Duchenne muscular dystrophy. Crucially, these results surpassed the performance observed with givinostat, a drug that has already received approval.
These diverse clinical and scientific developments have garnered attention from major financial institutions. Analyst firms William Blair and Leerink Partners both issued follow-on reports that reiterated an 'Outperform' rating on Tenaya Therapeutics. Specifically, William Blair emphasized regulatory alignment as a primary catalyst for the stock. Concurrently, Leerink Partners maintained a price target of $2.00 following Tenaya’s recent financial disclosures.
The cumulative weight of these clinical milestones and analyst endorsements indicates that Tenaya is navigating a period marked by intense activity across its therapeutic pipeline.